The National Oncology Institute in Sabratha, Libya, has announced the availability of specialized genetic analyses and tests for cancer diagnosis and treatment. This development is a result of collaboration with international companies, aiming to adopt precision medicine techniques. These techniques will enable the creation of tailored treatment plans for patients. The institute's efforts focus on enhancing cancer care through advanced genetic testing.

The genetic tests offered by the institute include analyses for BRCA1 and BRCA2 mutations. These mutations are associated with breast, ovarian, prostate, and pancreatic cancers. The tests also assess the genetic risks for families. Additionally, the institute provides HRD analysis. This analysis evaluates the suitability of ovarian cancer patients for targeted therapy using PARP inhibitors. Such targeted treatments can improve patient outcomes.

Further genetic tests available at the institute include KRAS mutation analysis for colorectal cancer patients. This analysis determines the suitability of treatments targeting EGFR receptors. Moreover, the institute offers EGFR mutation analysis for non-small cell lung cancer patients. These tests help in identifying patients who are more likely to respond to specific treatments. This personalized approach can minimize unnecessary side effects.

The National Oncology Institute's initiative to provide advanced genetic testing is a significant step forward in Libya's healthcare sector. By adopting precision medicine, the institute aims to improve cancer treatment outcomes. Patients will benefit from more accurate diagnoses and tailored treatment plans. This approach can lead to better patient care and more efficient use of resources.

The collaboration with international companies brings advanced medical technologies to Libya. This partnership enhances the institute's capacity to provide high-quality genetic testing and cancer care. The institute's efforts are expected to set a new standard for cancer treatment in the region. Patients from across Libya can now access these specialized services.

The availability of these genetic tests in Libya reduces the need for patients to seek medical care abroad. This development is expected to improve healthcare outcomes for cancer patients in the country. The institute's services will contribute to the advancement of precision medicine in Libya. As a result, patients will have better access to cutting-edge treatments.

The National Oncology Institute in Sabratha continues to play a crucial role in enhancing cancer care in Libya. Through its collaboration with international partners, the institute remains at the forefront of medical advancements. The introduction of advanced genetic analyses for cancer diagnosis and treatment underscores the institute's commitment to providing high-quality patient care.

Key points

  • The National Oncology Institute in Sabratha offers specialized genetic analyses for cancer diagnosis and treatment in collaboration with international companies.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.